Education
About Us
Working with TipRanks
Follow Us
RegenXBio (RGNX)
NASDAQ:RGNX
RGNX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.04 - $12.22
Previous CloseN/A
Volume155.59K
Average Volume (3M)547.23K
Market Cap
$526.86M
Enterprise Value$371.07M
Total Cash (Recent Filing)$323.30M
Total Debt (Recent Filing)$271.69M
Price to Earnings (P/E)―
Beta2.19
Next Earnings
Nov 05, 2025EPS Estimate
-1.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding50,514,217
10 Day Avg. Volume604,770
30 Day Avg. Volume547,225
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue2.38
Enterprise Value/Gross Profit2.98
Enterprise Value/Ebitda-2.86
Forecast
1Y Price Target
$25.67Price Target Upside146.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPositive 12-month data from the Phase 1/2/3 CAMPSIITE trial support the use of CSF HS D2S6 as a surrogate endpoint, indicating likely clinical benefit under the accelerated approval pathway.
Commercial PotentialIf approved, RGX-121 would be the first and only potential one-time, commercially-available therapy designed to directly address the underlying genetic cause of Hunter syndrome.
Regulatory AdvancementsRGX-121 has received Orphan Drug, Rare Pediatric Disease, Fast Track, and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA, enhancing its regulatory profile.
Bears Say
Market OpportunityShare impact will likely be muted as commercial opportunity in MPS II is modest and RGNX monetized the majority of its economic interest through strategic partnership with Nippon Shinyaku.
Regulatory DelaysThe FDA has extended its review timeline of the Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121) as a first-in-class gene therapy for Mucopolysaccharidosis II (MPS II, aka Hunter syndrome).
Regulatory TimelineFDA extended BLA review of clemidsogene lanparvovec (RGX-121) for Mucopolysaccharidosis II, pushing the PDUFA date to February 8, 2026.
RegenXBio News
RGNX FAQ
What was RegenXBio’s price range in the past 12 months?
RegenXBio lowest stock price was $5.04 and its highest was $12.22 in the past 12 months.
What is RegenXBio’s market cap?
RegenXBio’s market cap is $526.86M.
When is RegenXBio’s upcoming earnings report date?
RegenXBio’s upcoming earnings report date is Nov 05, 2025 which is in 31 days.
How were RegenXBio’s earnings last quarter?
RegenXBio released its earnings results on Aug 07, 2025. The company reported -$1.38 earnings per share for the quarter, missing the consensus estimate of -$0.938 by -$0.442.
Is RegenXBio overvalued?
According to Wall Street analysts RegenXBio’s price is currently Undervalued.
Does RegenXBio pay dividends?
RegenXBio does not currently pay dividends.
What is RegenXBio’s EPS estimate?
RegenXBio’s EPS estimate is -1.3.
How many shares outstanding does RegenXBio have?
RegenXBio has 50,514,217 shares outstanding.
What happened to RegenXBio’s price movement after its last earnings report?
RegenXBio reported an EPS of -$1.38 in its last earnings report, missing expectations of -$0.938. Following the earnings report the stock price went down -4.01%.
Which hedge fund is a major shareholder of RegenXBio?
Currently, no hedge funds are holding shares in RGNX
RegenXBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.67 (146.12% Upside)
$25.67 (146.12% Upside)
Blogger Sentiment
Bullish
RGNX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 58.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.9%
Last 30 Days ▲ 6.9%
Last 30 Days ▲ 6.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.55%
12-Months-Change
Fundamentals
Return on Equity
-62.49%
Trailing 12-Months
Asset Growth
2.05%
Trailing 12-Months
Company Description
RegenXBio
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
RGNX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong clinical progress and strategic partnerships. However, uncertainties around regulatory processes and competitive pressures create some challenges. The company is well-positioned financially and operationally to advance its pipeline.View all RGNX earnings summariesRGNX Stock 12 Month Forecast
Average Price Target
$25.67
▲(146.12% Upside)
Technical Analysis
Solid Biosciences
―
Monopar Therapeutics Inc
―
Opthea Limited Sponsored ADR
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
8.76% Insiders
18.98% Mutual Funds
20.70% Other Institutional Investors
38.59% Public Companies and Individual Investors